According to Zacks, “Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. “
A number of other equities research analysts have also recently issued reports on MD. Goldman Sachs Group Inc started coverage on shares of MEDNAX in a research report on Friday, December 9th. They issued a neutral rating and a $66.00 target price for the company. Jefferies Group LLC cut shares of MEDNAX from a buy rating to a hold rating and reduced their target price for the company from $75.00 to $70.00 in a research report on Tuesday, December 13th. Finally, JPMorgan Chase & Co. reissued a neutral rating and issued a $69.00 target price on shares of MEDNAX in a research report on Friday, March 10th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $68.50.
Shares of MEDNAX (NYSE:MD) traded down 1.02% on Wednesday, hitting $69.83. 209,062 shares of the stock traded hands. The stock has a market cap of $6.48 billion, a PE ratio of 20.01 and a beta of 0.67. MEDNAX has a 1-year low of $59.36 and a 1-year high of $76.96. The stock has a 50 day moving average of $69.55 and a 200-day moving average of $66.86.
MEDNAX (NYSE:MD) last announced its earnings results on Tuesday, February 7th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.06. The business earned $831 million during the quarter, compared to the consensus estimate of $842.15 million. MEDNAX had a net margin of 10.21% and a return on equity of 13.59%. The company’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.13 EPS. On average, equities research analysts expect that MEDNAX will post $4.25 EPS for the current year.
Your IP Address:
In related news, Director Md Pascal J. Goldschmidt sold 25,294 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $67.82, for a total transaction of $1,715,439.08. Following the completion of the sale, the director now owns 14,173 shares of the company’s stock, valued at $961,212.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Vivian Lopez-Blanco sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $70.95, for a total transaction of $709,500.00. Following the sale, the chief financial officer now directly owns 74,261 shares of the company’s stock, valued at approximately $5,268,817.95. The disclosure for this sale can be found here. Insiders have sold 96,296 shares of company stock valued at $6,668,891 in the last ninety days. 2.40% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in MEDNAX by 6.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 8,034,055 shares of the company’s stock valued at $532,256,000 after buying an additional 508,260 shares in the last quarter. BlackRock Fund Advisors boosted its stake in MEDNAX by 2.4% in the third quarter. BlackRock Fund Advisors now owns 3,664,544 shares of the company’s stock valued at $242,776,000 after buying an additional 86,578 shares in the last quarter. Nordea Investment Management AB boosted its stake in MEDNAX by 2.1% in the third quarter. Nordea Investment Management AB now owns 2,878,350 shares of the company’s stock valued at $190,691,000 after buying an additional 60,410 shares in the last quarter. 1832 Asset Management L.P. boosted its stake in MEDNAX by 2.0% in the third quarter. 1832 Asset Management L.P. now owns 2,394,095 shares of the company’s stock valued at $158,417,000 after buying an additional 46,296 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in MEDNAX by 17,600.5% in the third quarter. Victory Capital Management Inc. now owns 1,443,301 shares of the company’s stock valued at $95,619,000 after buying an additional 1,435,147 shares in the last quarter. 99.16% of the stock is owned by institutional investors and hedge funds.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network is composed of affiliated physicians, including those providing neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/mednax-inc-md-upgraded-at-zacks-investment-research/1709088.html
Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.